Reviva Pharmaceuticals Holdings, Inc. financial data

Symbol
RVPH, RVPHW on Nasdaq
Industry
Pharmaceutical Preparations
Location
10080 N Wolfe Road, Suite Sw3 200, Cupertino, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
Tenzing Acquisition Corp. (to 12/14/2020)
Latest financial report
10-Q - Q3 2024 - Nov 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity -554 % +52.3%
Return On Assets -250 % +23.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 33.4M shares +47.6%
Common Stock, Shares, Outstanding 33.4M shares +61.9%
Entity Public Float 104M USD
Common Stock, Value, Issued 3.34K USD +47.6%
Weighted Average Number of Shares Outstanding, Basic 33.8M shares +43%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 26.3M USD -16.7%
General and Administrative Expense 7.8M USD -3.08%
Operating Income (Loss) -34.1M USD +13.9%
Nonoperating Income (Expense) 1.13M USD -58%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -33M USD +21.3%
Income Tax Expense (Benefit) 10.2K USD -65.9%
Net Income (Loss) Attributable to Parent -33M USD +17.5%
Earnings Per Share, Basic -1.1 USD/shares +38.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 5.56M USD +11.8%
Assets, Current 6.81M USD
Assets 7.63M USD +41.6%
Accounts Payable, Current 8.78M USD +66.3%
Employee-related Liabilities, Current 882K USD
Liabilities, Current 17.5M USD +1.21%
Liabilities 17.6M USD -3.22%
Retained Earnings (Accumulated Deficit) -158M USD -26.4%
Stockholders' Equity Attributable to Parent -9.98M USD +22.1%
Liabilities and Equity 7.63M USD +41.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -11.7M USD -47.5%
Net Cash Provided by (Used in) Financing Activities 332K USD -51.7%
Common Stock, Shares Authorized 115M shares 0%
Common Stock, Shares, Issued 33.4M shares +61.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Interest Paid, Excluding Capitalized Interest, Operating Activities 3.49K USD
Deferred Tax Assets, Valuation Allowance 27.5M USD +58.7%
Deferred Tax Assets, Gross 27.5M USD +58.7%
Depreciation 0 USD
Deferred Tax Assets, Operating Loss Carryforwards 15.3M USD +20.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares
Additional Paid in Capital 148M USD +31.9%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 1.47M USD -52.4%
Interest Expense 3.49K USD -54.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares